[1]詹 颉a,马少君b,刘延梅c.HER2/neu扩增和淋巴管浸润(LVI)在T1乳腺癌腋窝淋巴结转移的预测价值[J].现代检验医学杂志,2015,30(03):87-89.[doi:10.3969/j.issn.1671-7414.2015.03.025]
 ZHAN Jiea,MA Shao-junb,LIU Yan-meic.Predictive Value of HER2/neu Amplification and Lymphovascular Invasion for Axillary Lymph Node Metastasis in Early Breast Cancer Patients[J].Journal of Modern Laboratory Medicine,2015,30(03):87-89.[doi:10.3969/j.issn.1671-7414.2015.03.025]
点击复制

HER2/neu扩增和淋巴管浸润(LVI)在T1乳腺癌腋窝淋巴结转移的预测价值()
分享到:

《现代检验医学杂志》[ISSN:/CN:]

卷:
第30卷
期数:
2015年03期
页码:
87-89
栏目:
论著
出版日期:
2015-06-10

文章信息/Info

Title:
Predictive Value of HER2/neu Amplification and Lymphovascular Invasion for Axillary Lymph Node Metastasis in Early Breast Cancer Patients
文章编号:
1671-7414(2015)03-087-03
作者:
詹 颉a马少君b刘延梅c
陕西省人民医院 a.检验科; b.放射科; c.西院病区,西安 710068
Author(s):
ZHAN JieaMA Shao-junbLIU Yan-meic
a.Department of Clinical Laboratory;
b.Department of Radiology;
c.Department of West Ward,Shaanxi Provincial People's Hospital,Xi'an 710068,China
关键词:
乳腺肿瘤 HER2/neu 淋巴管浸润
分类号:
R737.9; R730.43
DOI:
10.3969/j.issn.1671-7414.2015.03.025
文献标志码:
A
摘要:
目的 探讨HER2/neu扩增和淋巴管浸润(LVI)在T1期(肿块小于2 cm)乳腺癌腋窝淋巴结转移中的预测价值。方法 将206例有或无淋巴结转移的T1乳腺癌患者应用免疫组织化学(IHC)、荧光原位杂交(FISH)及临床病理因素相关性如年龄、肿瘤大小(T1a,T1b,T1c)、组织学分级,核分级、淋巴管浸润(LVI)、雌激素和孕激素受体状态、HER2/neu表达、Ki-67标记指数和Bcl-2表达进行分析,探讨各项因素与T1期乳腺癌腋窝淋巴结转移的相关性。结果 206例T1乳腺癌患者中139例淋巴结阴性(T1N0),其余67例淋巴结阳性(T1N1-3),年龄(χ2=6.484,P= 0.011),LVI(χ2=72.813,P<0.001),组织学分级(χ2=74.813,P=0.019),HER2/neu(χ2=72.813,P<0.005),Ki-67(χ2=6.255,P=0.012)和Bcl-2(χ2=4.977,P=0.026)的表达,LVI和HER2/neu是有显著统计学意义的淋巴结转移预测因素,而诸如肿瘤大小(χ2=1.544,P=0.254)、手术方法(χ2=2.414,P=0.120)、核分级HG(χ2=2.017,P=0.159)、ERC雌激素受体(χ2=0.140,P=0.709)、PgR孕激素受体(χ2=2.199,P=0.145)则与早期乳腺癌淋巴结转移无明显统计学相关性。结论 HER2/neu过度表达和淋巴管浸润LVI与T1期乳腺癌患者淋巴结转移相关,LVI是临床最有价值预测性因素。
Abstract:
Objective To study the predictive value of HER2/neu amplification and lymphovascular invasion for axillary lymph node metastasis in T1 breast cancer patients(mass<2 cm).Methods Reviewed the medical record of 206 T1 breast cancer patients who were the presence or absence of lymph node metastasis with IHC and FISH,analyzed the association between ALNM and various clinicopathological predictive factors such as age,tumorsize(T1a,T1b,T1c),multiplicity,the histologic grade,the nuclear grade,thepresence of lymphovascular invasion(LVI),the estrogen and progesterone receptor status,an HER2/neu expression,the Ki-67 labeling index and the bcl-2 expression,and discussed the correlation of the various factors with axillary lymphnode metastasis of T1 breast cancer.Results One hundredand thirty-nine were the node negative group(T1N0)and the remaining 67 caseswere allotted to the node positive group(T1N1-3),age(χ2=6.484,P=0.011),LVI(χ2=72.813,P<0.001),histologic grade(χ2=74.813,P=0.019),HER2/neu(χ2=74.813,P<0.005),Ki-67(χ2=6.255,P=0.012)and bcl-2(χ2=4.977,P=0.026)were the statistically significant predictive factors related to node metastasis.The factors such as tumor size(χ2=1.544,P=0.254),surgical method(χ2=2.414,P=2.414),anduclear grading HG(χ2=2.017,P=0.159),estrogen receptors ER(χ2=0.140,P=0.709),progesterone receptor PgR(χ2=2.199,P=2.199),have no significant statistical correlation with early breast cancer lymph node metastasis.Conclusion HER2/neu overexpression and LVI wererelated to the increased incidence of ALNM in T1 breast cancer patients,LVI wasthe most predictive factor of ALNM.

参考文献/References:

[1] Rosen PP, Saigo PE, Braun DW,et al.Prognosis in stage II(T1N1M0)breast cancer[J].Ann Surg,1981,194(5):576-584.
[2] González-Vela MC,Garijo MF,Fernández FA,et al.Predictors of axillary lymph node metastases in patients with invasive breast carcinoma by a combination of classical and biological prognostic factors[J].Pathol Res Pract,1999,195(9):611-618.
[3] Tan LG,Tan YY,Heng D,et al.Predictors of axillary lymph node metastases in women with early breast cancer in Singapore[J].Singapore Medical Journal,2006,46(12):693-697.
[4] Port ER,Tan LK,Borgen PI,et al.Incidence of axillary lymph node metastases in T1a and T1b breast carcinoma[J].Ann Surg Oncol,1998,5(1):23-27.
[5] Quint LE. Imaging of anterior mediastinal masses[J].Cancer Imaging,7(Spec No A):S56-62.
[6] Lee AH,Pinder SE,Macmillan RD,et al.Prognostic value of lymphovascular invasion in women with lymph node negative invasive breast carcinoma[J].EurJ Cancer,2006,42(3):357-362.
[7] Lyman GH,Giuliano AE,Somerfield MR,et al.Am-erican Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer[J].J Clin Oncol,2005,23(30):7703-7720.
[8] Carcoforo P,Maestroni U,Querzoli P,et al.Primary breast cancer features can predict additional lymph node involvement in patiets with sentinel node micrometastases[J].World Journal of Surgery,2006,30(9):1653-1657.
[9] Mustac E,Matusan-Ilijas K,Marijic B,et al.Predicting the likelihoodof additional nodal metastases in breast carcinoma patients with positive sentinel node biopsy[J].Int J Surg Pathol,2010,18(1):36-41.
[10] Wasif N,Ye X,Giuliano AE,et al.Survey of ASCO members on management of sentinel node micrometastases in breast cancer:variation in treatment recommendations according to specialty[J].Annals of Surgical Oncology,2009,16(9):2442-2449.
[11] Park K, Kwak K, Kim J,et al.C-myc amplification is associated withHER2 amplification and closely linked with cell?proliferation in tissue miroarray of nonselected breast cancers[J].Hum Pathol,2005,36(6):634-639.

相似文献/References:

[1]王 倩,劳淑贞,朴金松,等.乳腺良恶性肿瘤组织中CD44的表达及其与淋巴管生成的关系[J].现代检验医学杂志,2018,33(04):16.[doi:10.3969/j.issn.1671-7414.2018.04.005]
 WANG Qian,LAO Shu-zhen,PIAO Jin-song,et al.Expression of CD44 in Benign and Malignant Breast Tumors and Its Relationship with Lymphangiogenesis[J].Journal of Modern Laboratory Medicine,2018,33(03):16.[doi:10.3969/j.issn.1671-7414.2018.04.005]
[2]林帝金,刘纯岳,方俊粤,等.乳腺肿瘤患者外周血中T淋巴细胞表面活化分子和Tregs的表达研究[J].现代检验医学杂志,2018,33(05):31.[doi:10.3969/j.issn.1671-7414.2018.05.009]
 LIN Di-jin,LIU Chun-yue,FANG Jun-yue,et al.Expression of T Lymphocyte Surface Activating Molecules and Tregs in Peripheral Blood of Patients with Breast Neoplass[J].Journal of Modern Laboratory Medicine,2018,33(03):31.[doi:10.3969/j.issn.1671-7414.2018.05.009]

备注/Memo

备注/Memo:
作者简介:詹 颉(1971-),女,本科,主管技师,主要从事临床医学检验工作。
通讯作者:马少君(1975-),男,本科,副主任医师。
更新日期/Last Update: 2015-06-10